Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 3,121–3,128 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Oncolytics Biotech Inc. Pelareorep with KEYTRUDA (pembrolizumab) - (NU 18I01) Pancreatic cancer Phase 2 Trial Completed Intravenous Oncology
Oncopeptides Pepaxto (melphalan flufenamide) - (OCEAN) Multiple myeloma Phase 3 Intravenous Oncology
OncoSec Medical Incorporated TAVO and KEYTRUDA - (KEYNOTE-695) Melanoma - cancer Phase 2b TAVO intratumoral KEYTRUDA intravenous Oncology
OncoSec Medical Incorporated TAVO-EP and KEYTRUDA Neoadjuvant treatment for melanoma Phase 2 TAVO-EP intratumoral KEYTRUDA intravenous Oncology
OncoSec Medical Incorporated Tavo + OPDIVO (nivolumab) Neoadjuvant Therapy for Melanoma Phase 2 Intratumoral and intravenous Oncology
OncoSec Medical Incorporated TAVO + epacadostat + KEYTRUDA (pembrolizumab) - (TRIFECTA) Head and Neck Squamous Cell Carcinoma Phase 2 Intratumoral for TAVO oral for epacadostat intravenous for KEYTRUDA Oncology
OncoSec Medical Incorporated TAVO + KEYTRUDA (pembrolizumab) - KEYNOTE-890 Triple negative breast cancer (TNBC) Phase 2 Intratumoral and intravenous Oncology
OnKure Therapeutics Inc. Mavodelpar (REN001) - (STRIDE) Primary mitochondrial myopathies (PMM) Phase 2b Trial Discontinued Oral Genetic Disorder